ArticleHepatology communications2020
Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients.
Article in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline.Clinical and molecular hepatology · 2021Guideline
- Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies.BMJ open gastroenterology · 2021Pooled it
- Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis.World journal of hepatology · 2026Article
- Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.Frontiers in immunology · 2025Review
- Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis.Biosafety and health · 2024Article
- Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.Hepatology forum · 2024Review
- Review
- Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors.Immunity, inflammation and disease · 2023Article
- COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations.World journal of hepatology · 2023Review
- Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19.World journal of clinical cases · 2023Review
- Autoimmune liver diseases and SARS-CoV-2.World journal of gastroenterology · 2023Review
- Review
- Coronavirus Disease-2019 and Implications on the Liver.Clinics in liver disease · 2023Review
- Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study.World journal of hepatology · 2023Article
- COVID-19: Has the Liver Been Spared?International journal of molecular sciences · 2023Review
- Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention.Hepatic medicine : evidence and research · 2023Review
- Molecular mechanisms implicated in SARS-CoV-2 liver tropism.World journal of gastroenterology · 2022Review
- Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective.World journal of virology · 2022Review
- COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic immunosuppression is associated with increased and more severe viral infections. However, little is known about the association between immunosuppression and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our aim was to describe the clinical course of patients with immunosuppressed autoimmune hepatitis (AIH) during coronavirus disease 2019 (COVID-19) infection in Italy. Our study is a case series of patients with AIH treated with immunosuppression, who tested positive for SARS-CoV-2 in March 2020 during the outbreak of COVID-19. Ten patients from seven different hospitals in Italy were diagnosed with COVID-19 during the outbreak of SARS-CoV-2 in March 2020. Seven subjects were female (70%), and age ranged from 27 to 73 years. Before the onset of SARS-CoV-2 infection, all patients were taking immunosuppressive therapy for AIH, and eight of them were on biochemical remission. Two other patients had recent acute onset of their AIH, and consequently started high-dose steroids, as per induction protocol. All patients had a respiratory syndrome and a positive nasal swab for SARS-CoV-2. Five patients developed a computed tomography-confirmed COVID-19 pneumonia. Six subjects received a combination of antiretroviral and antimalarial drugs. In seven patients, the dosage of immunosuppressive medication was changed. Liver enzymes were repeated during SARS-CoV-2 infection in all hospitalized cases; they remained within the normal range in all cases, and improved in the two acute cases treated with high-dose steroids. The clinical outcome was comparable to the reported cases occurring in non-immunosuppressed subjects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.